SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Sees Significant Decrease in Short Interest

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) was the target of a large decline in short interest during the month of February. As of February 15th, there was short interest totalling 8,650,000 shares, a decline of 11.8% from the January 31st total of 9,810,000 shares. Based on an average daily trading volume, of 2,700,000 shares, the days-to-cover ratio is currently 3.2 days.

SELLAS Life Sciences Group Stock Performance

Shares of NASDAQ:SLS remained flat at $1.19 during midday trading on Friday. The stock had a trading volume of 667,427 shares, compared to its average volume of 3,229,429. The company has a market capitalization of $83.75 million, a PE ratio of -1.72 and a beta of 2.43. SELLAS Life Sciences Group has a fifty-two week low of $0.77 and a fifty-two week high of $1.84. The firm has a fifty day simple moving average of $1.18 and a 200 day simple moving average of $1.18.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd acquired a new position in shares of SELLAS Life Sciences Group during the 3rd quarter valued at about $78,000. Virtu Financial LLC increased its stake in shares of SELLAS Life Sciences Group by 24.1% during the 3rd quarter. Virtu Financial LLC now owns 79,241 shares of the company's stock valued at $99,000 after acquiring an additional 15,398 shares during the last quarter. Northern Trust Corp increased its stake in shares of SELLAS Life Sciences Group by 33.6% during the 4th quarter. Northern Trust Corp now owns 134,721 shares of the company's stock valued at $140,000 after acquiring an additional 33,878 shares during the last quarter. State Street Corp grew its holdings in shares of SELLAS Life Sciences Group by 30.2% during the 3rd quarter. State Street Corp now owns 174,529 shares of the company's stock worth $218,000 after purchasing an additional 40,500 shares during the period. Finally, Opus Capital Group LLC grew its holdings in shares of SELLAS Life Sciences Group by 5.5% during the 4th quarter. Opus Capital Group LLC now owns 238,500 shares of the company's stock worth $248,000 after purchasing an additional 12,400 shares during the period. Institutional investors and hedge funds own 17.38% of the company's stock.

Remove Ads

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.